Literature DB >> 11244047

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

C A Chambers1, M S Kuhns, J G Egen, J P Allison.   

Abstract

The T cell compartment of adaptive immunity provides vertebrates with the potential to survey for and respond specifically to an incredible diversity of antigens. The T cell repertoire must be carefully regulated to prevent unwanted responses to self. In the periphery, one important level of regulation is the action of costimulatory signals in concert with T cell antigen-receptor (TCR) signals to promote full T cell activation. The past few years have revealed that costimulation is quite complex, involving an integration of activating signals and inhibitory signals from CD28 and CTLA-4 molecules, respectively, with TCR signals to determine the outcome of a T cell's encounter with antigen. Newly emerging data suggest that inhibitory signals mediated by CTLA-4 not only can determine whether T cells become activated, but also can play a role in regulating the clonal representation in a polyclonal response. This review primarily focuses on the cellular and molecular mechanisms of regulation by CTLA-4 and its manipulation as a strategy for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244047     DOI: 10.1146/annurev.immunol.19.1.565

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  290 in total

1.  Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling.

Authors:  Xuewu Zhang; Jean-Claude D Schwartz; Steven C Almo; Stanley G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

Review 2.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

3.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 4.  A sense of tumour for the immune system.

Authors:  Stephen Todryk
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

5.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

Review 6.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

7.  Manipulating Memory CD8 T Cell Numbers by Timed Enhancement of IL-2 Signals.

Authors:  Marie T Kim; Samarchith P Kurup; Gabriel R Starbeck-Miller; John T Harty
Journal:  J Immunol       Date:  2016-07-20       Impact factor: 5.422

Review 8.  [Immunotherapy of melanomas].

Authors:  L Zimmer; J Vaubel; D Schadendorf
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

9.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

10.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Authors:  Lili Yang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.